drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A HER3-targeted antibody-drug conjugate administered IV every 3 weeks in a Phase 1 dose escalation/expansion study. It is an anti-HER3 (ERBB3) monoclonal antibody that is internalized upon binding HER3 on tumor cells and releases a topoisomerase I inhibitor payload to induce DNA damage and apoptosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER3-targeted monoclonal antibody binds ERBB3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload that inhibits Topo I, causing DNA damage (replication-associated strand breaks) and apoptosis.
drug_name
SIBP-A13
nct_id_drug_ref
NCT06298058